糖心vlog传媒

logo

Indonesia Diabetes Care Drugs Market Size (2024 - 2029)

The Indonesia Diabetes Care Drugs Market is projected to experience growth over the forecast period, driven by the increasing need for effective diabetes management solutions. The market's expansion is influenced by challenges such as health literacy disparities and the impact of the COVID-19 pandemic on diabetes care. Efforts by local governments and health organizations to improve access and management of diabetes are crucial, as the rising prevalence of the disease and its complications contribute to higher healthcare costs and a greater demand for care.

Home Market Analysis Healthcare Research Pharmaceuticals Research Disease Specific Drugs Research Chronic Disorder Drugs Research Diabetes Care Drugs Research Indonesia Insulin Market Market Size

Market Size of Indonesia Diabetes Care Drugs Industry

Indonesia Diabetes Care Drugs Market Summary
Study Period 2019 - 2029
Base Year For Estimation 2023
Forecast Data Period 2024 - 2029
Market Size (2024) USD 301.55 Million
Market Size (2029) USD 370.43 Million
CAGR (2024 - 2029) 4.20 %

Major Players

rd-img

*Disclaimer: Major Players sorted in no particular order

Indonesia Diabetes Care Drugs Market Analysis

The Indonesia Diabetes Care Drugs Market size is estimated at USD 301.55 million in 2024, and is expected to reach USD 370.43 million by 2029, growing at a CAGR of 4.20% during the forecast period (2024-2029).

Inequality in the management of diabetes in Indonesia existed before the COVID-19 pandemic. The gap in health literacy was a major factor in the disparity in managing chronic diseases. The Pandemic brought about more challenges to pre-existing conditions. Diabetes was one of the most common factors linked to COVID-19; consistent evidence suggested that diabetes increased the risk of COVID-19. Higher blood glucose levels were associated with the worst COVID-19 outcomes. Tight control of glucose levels proved crucial in patients with diabetes mellitus to prevent progression to severe COVID-19. Therefore, improving the management of diabetes during the Pandemic became important by improving health literacy and providing adequate access.

Diabetic drugs are medicines developed to stabilize and control blood glucose levels among people with diabetes. Diabetic drugs are commonly used to manage diabetes. Several classes of diabetes medicines exist. Each class of medicine has a different mechanism of action to lower blood sugar. A drug may work by causing the pancreas to make and release more insulin, limiting the liver's ability to make and release sugar, blocking the action of enzymes in the intestines that break down carbohydrates, improving cells' sensitivity to insulin, limiting the kidneys' ability to take in sugar, which increases the amount of sugar leaving the body in urine, etc.

Indonesian Diabetes Association and the Ministry of Health Indonesia are actively collaborating with the Indonesian local governments and diabetes care product manufacturers to remain available for all Indonesians. The rising number of people with diabetes implies an increased burden of the disease and its complications, such as heart disease, stroke, blindness, chronic kidney disease, and lower limb amputation. These result in reduced quality of life and higher healthcare costs, leading to a greater need for access to care.

Therefore, owing to the factors above, the studied market is anticipated to grow over the analysis period.

Indonesia Diabetes Care Drugs Industry Segmentation

Diabetes Drugs are used to manage diabetes mellitus by lowering the glucose level in the blood. The Indonesia Diabetes Care Drugs Market is segmented into drugs (Insulin, Oral anti-diabetic Drugs, Non-Insulin Injectable Drugs, and Combination Drugs). The report offers the value (USD) and volume (Units) for the above segments.

Oral Anti-diabetic drugs
Biguanides
Metformin
Alpha-Glucosidase Inhibitors
Alpha-Glucosidase Inhibitors
Dopamine D2 receptor agonist
Bromocriptin
SGLT-2 inhibitors
Invokana (Canagliflozin)
Jardiance (Empagliflozin)
Farxiga/Forxiga (Dapagliflozin)
Suglat (Ipragliflozin)
DPP-4 inhibitors
Onglyza (Saxagliptin)
Tradjenta (Linagliptin)
Vipidia/Nesina(Alogliptin)
Galvus (Vildagliptin)
Sulfonylureas
Sulfonylureas
Meglitinides
Meglitinides
Insulins
Basal or Long Acting Insulins
Lantus (Insulin Glargine)
Levemir (Insulin Detemir)
Toujeo (Insulin Glargine)
Tresiba (Insulin Degludec)
Basaglar (Insulin Glargine)
Bolus or Fast Acting Insulins
NovoRapid/Novolog (Insulin Aspart)
Humalog (Insulin Lispro)
Apidra (Insulin Glulisine)
Traditional Human Insulins
Novolin/Actrapid/Insulatard
Humulin
Insuman
Biosimilar Insulins
Insulin Glargine Biosimilars
Human Insulin Biosimilars
Combination drugs
Insulin combinations
NovoMix (Biphasic Insulin Aspart)
Ryzodeg (Insulin Degludec and Insulin Aspart)
Xultophy (Insulin Degludec and Liraglutide)
Oral Combinations
Janumet (Sitagliptin and Metformin)
Non-Insulin Injectable drugs
GLP-1 receptor agonists
Victoza (Liraglutide)
Byetta (Exenatide)
Bydureon (Exenatide)
Trulicity (Dulaglutide)
Lyxumia (Lixisenatide)
Amylin Analogue
Symlin (Pramlintide)
Need A Different Region Or Segment?
Customize Now

Indonesia Diabetes Care Drugs Market Size Summary

The Indonesia Diabetes Care Drugs Market is poised for growth, driven by the increasing prevalence of diabetes and the need for effective management solutions. The market is characterized by a diverse range of diabetic drugs designed to stabilize and control blood glucose levels, with oral antidiabetic drugs holding a significant share due to their efficacy, safety, and cost-effectiveness. The collaboration between the Indonesian Diabetes Association, the Ministry of Health, and local governments aims to enhance health literacy and access to care, addressing the disparities exacerbated by the COVID-19 pandemic. The market landscape is moderately consolidated, with major players like Eli Lilly, Sanofi, Novo Nordisk, and AstraZeneca leading the charge, alongside regional generic manufacturers.

The market's expansion is further supported by the introduction of innovative therapies such as Sodium-dependent Glucose Cotransporter 2 (SGLT-2) inhibitors, which offer additional benefits like cardiovascular risk management and weight loss. Despite challenges in primary care services and health literacy, initiatives like the PROLANIS program aim to improve diabetes self-management under the national health insurance scheme. The ongoing development and approval of new drugs, such as Daewoong Pharmaceutical's SGLT2 enzyme inhibitor, highlight the dynamic nature of the market. As Indonesia continues to grapple with the dual burden of communicable and non-communicable diseases, the diabetes care drugs market is expected to grow, driven by both demand for effective treatments and strategic collaborations among key stakeholders.

Explore More

Indonesia Diabetes Care Drugs Market Size - Table of Contents

  1. 1. MARKET DYNAMICS

    1. 1.1 Market Overview

    2. 1.2 Market Drivers

    3. 1.3 Market Restraints

    4. 1.4 Porter's Five Forces Analysis

      1. 1.4.1 Bargaining Power of Suppliers

      2. 1.4.2 Bargaining Power of Consumers

      3. 1.4.3 Threat of New Entrants

      4. 1.4.4 Threat of Substitute Products and Services

      5. 1.4.5 Intensity of Competitive Rivalry

  2. 2. MARKET SEGMENTATION

    1. 2.1 Oral Anti-diabetic drugs

      1. 2.1.1 Biguanides

        1. 2.1.1.1 Metformin

      2. 2.1.2 Alpha-Glucosidase Inhibitors

        1. 2.1.2.1 Alpha-Glucosidase Inhibitors

      3. 2.1.3 Dopamine D2 receptor agonist

        1. 2.1.3.1 Bromocriptin

      4. 2.1.4 SGLT-2 inhibitors

        1. 2.1.4.1 Invokana (Canagliflozin)

        2. 2.1.4.2 Jardiance (Empagliflozin)

        3. 2.1.4.3 Farxiga/Forxiga (Dapagliflozin)

        4. 2.1.4.4 Suglat (Ipragliflozin)

      5. 2.1.5 DPP-4 inhibitors

        1. 2.1.5.1 Onglyza (Saxagliptin)

        2. 2.1.5.2 Tradjenta (Linagliptin)

        3. 2.1.5.3 Vipidia/Nesina(Alogliptin)

        4. 2.1.5.4 Galvus (Vildagliptin)

      6. 2.1.6 Sulfonylureas

        1. 2.1.6.1 Sulfonylureas

      7. 2.1.7 Meglitinides

        1. 2.1.7.1 Meglitinides

    2. 2.2 Insulins

      1. 2.2.1 Basal or Long Acting Insulins

        1. 2.2.1.1 Lantus (Insulin Glargine)

        2. 2.2.1.2 Levemir (Insulin Detemir)

        3. 2.2.1.3 Toujeo (Insulin Glargine)

        4. 2.2.1.4 Tresiba (Insulin Degludec)

        5. 2.2.1.5 Basaglar (Insulin Glargine)

      2. 2.2.2 Bolus or Fast Acting Insulins

        1. 2.2.2.1 NovoRapid/Novolog (Insulin Aspart)

        2. 2.2.2.2 Humalog (Insulin Lispro)

        3. 2.2.2.3 Apidra (Insulin Glulisine)

      3. 2.2.3 Traditional Human Insulins

        1. 2.2.3.1 Novolin/Actrapid/Insulatard

        2. 2.2.3.2 Humulin

        3. 2.2.3.3 Insuman

      4. 2.2.4 Biosimilar Insulins

        1. 2.2.4.1 Insulin Glargine Biosimilars

        2. 2.2.4.2 Human Insulin Biosimilars

    3. 2.3 Combination drugs

      1. 2.3.1 Insulin combinations

        1. 2.3.1.1 NovoMix (Biphasic Insulin Aspart)

        2. 2.3.1.2 Ryzodeg (Insulin Degludec and Insulin Aspart)

        3. 2.3.1.3 Xultophy (Insulin Degludec and Liraglutide)

      2. 2.3.2 Oral Combinations

        1. 2.3.2.1 Janumet (Sitagliptin and Metformin)

    4. 2.4 Non-Insulin Injectable drugs

      1. 2.4.1 GLP-1 receptor agonists

        1. 2.4.1.1 Victoza (Liraglutide)

        2. 2.4.1.2 Byetta (Exenatide)

        3. 2.4.1.3 Bydureon (Exenatide)

        4. 2.4.1.4 Trulicity (Dulaglutide)

        5. 2.4.1.5 Lyxumia (Lixisenatide)

      2. 2.4.2 Amylin Analogue

        1. 2.4.2.1 Symlin (Pramlintide)

Indonesia Diabetes Care Drugs Market Size FAQs

The Indonesia Diabetes Care Drugs Market size is expected to reach USD 301.55 million in 2024 and grow at a CAGR of 4.20% to reach USD 370.43 million by 2029.

In 2024, the Indonesia Diabetes Care Drugs Market size is expected to reach USD 301.55 million.

Indonesia Diabetes Market Report Snapshots

Indonesia Diabetes Care Drugs Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)